Myriad Genetics, Inc.
MYGN
$3.84
-$0.27-6.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 99.62% | -36.22% | 63.95% | 68.39% | 52.47% |
| Total Depreciation and Amortization | -8.28% | -1.99% | 85.71% | 13.53% | -19.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -250.41% | 2,066.67% | -30.95% | 38.74% | -53.41% |
| Change in Net Operating Assets | 41.26% | 41.40% | -174.49% | -102.78% | 15.23% |
| Cash from Operations | 12.37% | 112.07% | 103.17% | 388.89% | 43.98% |
| Capital Expenditure | 20.90% | 64.00% | 67.89% | 72.34% | 71.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -650.00% | -15.00% | -73.81% | -103.92% | -100.69% |
| Cash from Investing | -16.90% | 50.83% | 400.00% | -154.24% | -120.52% |
| Total Debt Issued | -33.33% | -50.00% | -- | -50.00% | -- |
| Total Debt Repaid | 65.72% | 51.12% | -20,000.00% | -- | -- |
| Issuance of Common Stock | -- | -97.65% | -- | -- | -- |
| Repurchase of Common Stock | 33.33% | 20.00% | -36.36% | -150.00% | -77.55% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 254.55% | -98.28% | -24.00% | -93.75% | -79.59% |
| Foreign Exchange rate Adjustments | 112.50% | -200.00% | 300.00% | -333.33% | -500.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 69.12% | -96.24% | 131.05% | -108.87% | -969.70% |